ENTX_001
Nontuberculous Mycobacterial (NTM) Infections (MAC, M. abscessus)
Pre-clinicalActive
Key Facts
Indication
Nontuberculous Mycobacterial (NTM) Infections (MAC, M. abscessus)
Phase
Pre-clinical
Status
Active
Company
About Endolytix
Endolytix is a private, pre-clinical-stage biotech tackling the critical global health challenge of antibiotic resistance, specifically in difficult-to-treat mycobacterial infections. Its core innovation is a proprietary drug delivery platform that targets and eliminates intracellular bacteria hiding within macrophages, a mechanism not addressed by standard antibiotics. The company's lead program, ENTX_001, is designed to be synergistic with existing standard-of-care drugs. With a small team and a custom-built facility in Beverly, MA, Endolytix is positioned in a high-need market with significant projected growth in NTM infections.
View full company profile